EGFR and cancer: This novel EGFR-targeting enzymatic prodrug system, Fcy–hEGF/5-FC, displayed potential to be a potent inhibitor for treatment of EGFR-overexpressing cancers, while reducing the severe side effects of 5-FU [24].